Rhythm Biosciences (ASX:RHY) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Rhythm Biosciences Debt-to-Equity?

Rhythm Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.04 Mil. Rhythm Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Rhythm Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$1.24 Mil. Rhythm Biosciences's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Rhythm Biosciences's Debt-to-Equity or its related term are showing as below:

ASX:RHY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.03
Current: 0.03

During the past 6 years, the highest Debt-to-Equity Ratio of Rhythm Biosciences was 0.03. The lowest was 0.00. And the median was 0.02.

ASX:RHY's Debt-to-Equity is ranked better than
91.19% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs ASX:RHY: 0.03

Rhythm Biosciences Debt-to-Equity Historical Data

The historical data trend for Rhythm Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Biosciences Debt-to-Equity Chart

Rhythm Biosciences Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.01

Rhythm Biosciences Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial								-	0.02	0.02	0.01	0.03

Competitive Comparison of Rhythm Biosciences's Debt-to-Equity

For the Diagnostics & Research subindustry, Rhythm Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rhythm Biosciences's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's Debt-to-Equity falls into.

Rhythm Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Rhythm Biosciences's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.085	+	0)	/	5.874
	=	0.01

Rhythm Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.039	+	0)	/	1.243
	=	0.03

Rhythm Biosciences (ASX:RHY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Rhythm Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Rhythm Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhythm Biosciences (ASX:RHY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rhythm Biosciences Ltd (ASX:RHY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0RY:Germany

Address

30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010

Website

https://www.rhythmbio.com

Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

Rhythm Biosciences (ASX:RHY) Headlines

No Headlines